New drug combination for advanced stomach cancer after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (IBI363 plus Avastin) with or without chemotherapy (Abraxane) for people with advanced stomach or GE junction cancer that has already been treated with immunotherapy and other first-line therapy. The goal is to see if this new approach can help when the cancer has grown or stopped responding to prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have advanced stomach or gastroesophageal junction cancer that got worse after a first treatment that included immunotherapy.
- Your previous immunotherapy either didn't work well (stable disease less than 12 weeks or got worse) or worked but then stopped working within 6 months after the last dose.
- You need to have at least one tumor that can be measured with scans.
- Your blood and organ function must be within certain levels (like kidney, liver, and blood counts) within the week before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (apatinib, nab-paclitaxel, and possibly adebrelimab) for advanced stomach or gastroesophageal junction cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This study tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or GEJ cancer that continued to grow after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.